New US study data suggests exercise could increase lifespan after treatment for breast cancer

A new study conducted by researchers from the University of Southern California in Los Angeles, explains how aerobic and resistance exercise can increase life expectancy for patients who have successfully completed breast cancer treatment. According to National Cancer Institute estimates, in 2017 there were approximately 252,710 new diagnoses of breast cancer in the United States.

Continue Reading

NICE recommend Eisai’s lenvatinib for treatment of advanced renal cell carcinoma

Eisai announced that NICE has given a positive recommendation for the use of lenvatinib in combination with everolimus to treat adults with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy, if their Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1. The company also provides lenvatinib

Continue Reading

NICE disapproves Roche’s giant cell arteritis treatment, Roactemra, for use on the NHS

It is starting to look highly unlikely that patients with giant cell arteritis will gain NHS access to Roche’s Roactemra, due to the drug being turned down by cost regulators in draft guidelines. NICE’s appraisal committee has emphasised “substantial uncertainties” in the evidence on how long patients would have to take the treatment and what

Continue Reading

Three new treatments approved for use on NHS Scotland, including hepatitis C

Scottish Medicines Consortium (SMC) has published new advice accepting three new medicines for use by NHS Scotland, offering patients new treatment options for soft tissue sarcoma, acromegaly and hepatitis C. Eli Lilly’s Lartruvo was approved for the treatment of advanced soft tissue sarcoma, a rare type of cancer that affects the soft, supportive tissues within

Continue Reading